 NOVATO, Calif., Aug. 17, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 14,445 shares of common stock of the company and 4,815 restricted stock units of the companys common stock to two newly hired non-executive officer employees of the company. The awards were approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2021, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635c4. 